BCS II waiver approach [Dissolution / BCS / IVIVC]

posted by yuvaneshwari – India, 2019-01-23 06:09 (734 d 12:24 ago) – Posting: # 19801
Views: 2,101

Dear All,

Drug compound is BCS-II [dosage form is solution filled in capsule], and objective is to formulate with Q1 & Q2 sameness to that of Reference. Since API is in solution state filled in capsule, its solubility/bioavailability is improved tremendously.

In the above scenario, can we consider for BCS based waiver approach ?

Complete thread:

Activity
 Admin contact
21,314 posts in 4,446 threads, 1,489 registered users;
online 6 (2 registered, 4 guests [including 2 identified bots]).
Forum time: Tuesday 18:33 CET (Europe/Vienna)

Any one who considers arithmetical methods
of producing random digits is, of course,
in a state of sin.    John von Neumann

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5